Amgen, Inc.

Amgen, Inc. logo
🇺🇸United States
Ownership
Public
Established
1980-01-01
Employees
26.7K
Market Cap
$175.6B
Website
http://www.amgen.com
Clinical Trials
Related News

Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

First Posted Date
2011-06-27
Last Posted Date
2017-11-06
Lead Sponsor
Amgen
Target Recruit Count
35
Registration Number
NCT01380756
Locations
🇺🇸

Research Site, Houston, Texas, United States

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 3
Completed
Conditions
MDS
Interventions
Drug: Placebo
Drug: Darbepoetin alfa
First Posted Date
2011-05-30
Last Posted Date
2017-12-19
Lead Sponsor
Amgen
Target Recruit Count
147
Registration Number
NCT01362140
Locations
🇨🇭

Research Site, Zurich, Switzerland

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

First Posted Date
2011-04-08
Last Posted Date
2017-11-06
Lead Sponsor
Amgen
Target Recruit Count
35
Registration Number
NCT01331941
Locations
🇺🇸

Research Site, Cleveland, Ohio, United States

Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease

First Posted Date
2011-02-04
Last Posted Date
2020-06-17
Lead Sponsor
Amgen
Target Recruit Count
14
Registration Number
NCT01290029
Locations
🇬🇧

Research Site, Nottingham, United Kingdom

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

First Posted Date
2011-01-05
Last Posted Date
2024-12-13
Lead Sponsor
Amgen
Target Recruit Count
282
Registration Number
NCT01270347
Locations
🇺🇸

Childrens Hospital, Los Angeles, California, United States

🇺🇸

Albany Medical College #2, Albany, New York, United States

🇫🇷

Hôpital Pellegrin Enfants - CHU Bordeaux, Bordeaux, France

and more 31 locations

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: AMG 827
First Posted Date
2010-09-10
Last Posted Date
2021-11-26
Lead Sponsor
Amgen
Target Recruit Count
315
Registration Number
NCT01199289
Locations
🇷🇺

Research Site, Saint Petersburg, Russian Federation

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Phase 3
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: Aeroquin
Drug: Placebo
First Posted Date
2010-08-12
Last Posted Date
2024-12-18
Lead Sponsor
Amgen
Target Recruit Count
330
Registration Number
NCT01180634
Locations
🇦🇺

Westmead Chilren's Hospital, Westmead, New South Wales, Australia

🇺🇸

Childrens Hospital, Los Angeles, California, United States

🇦🇺

Mater Miscericordiae Hospital, Brisbane, Queensland, Australia

and more 11 locations

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

First Posted Date
2010-07-19
Last Posted Date
2014-09-16
Lead Sponsor
Amgen
Target Recruit Count
16
Registration Number
NCT01164917
Locations
🇺🇸

Research Site, Salt Lake City, Utah, United States

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

Phase 1
Completed
Conditions
Hyperlipidemia
Interventions
Biological: Placebo
Biological: Evolocumab
First Posted Date
2010-05-31
Last Posted Date
2018-11-02
Lead Sponsor
Amgen
Target Recruit Count
60
Registration Number
NCT01133522

An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density

Phase 1
Completed
Conditions
Osteopenia
Interventions
Drug: AMG 167
Drug: Placebo
First Posted Date
2010-04-09
Last Posted Date
2018-09-06
Lead Sponsor
Amgen
Target Recruit Count
74
Registration Number
NCT01101048
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy